Reminds me of the property Gurus that make more on their seminars than property
Printable View
Reminds me of the property Gurus that make more on their seminars than property
153 pages, Mmm, how much does that work out at per page?
Maybe he has an ''all weather'' computer
How about a cup of tea Shnaps ?
https://youtu.be/b6NkBpIYO1s
Looks like a final settlement on Actos has landed with the pharma Takeda agreeing to pay out.
A nice $2.4B, down from what could have been $9B, for 3900 individual claimants with bladder cancer, so thus $610k per patient each, cash in the hand.
Poor buggers though, money may or may not pay to fix what they have.
And then there are perhaps millions of Actos users out there in the world who haven’t presented with bladder cancer symptoms, as far as they may or may not be aware.
http://www.cxbladder.com/for-patient...ladder-cancer/
http://www.prnewswire.com/news-relea...300078757.html
There were literally thousands with diabetes in New Zealand alone prescribed with Actos medication;
http://www.3news.co.nz/world/nzers-i...#axzz3ZP32YGrA
If any of you may know anyone, or have a family member, it may be that your medical insurance may be willing to cover the cost of a screening Cxbladder test now that the connection with Actos has been both medically proven and litigated.
You could save a life, particularly if that person may also have other risk factors, be a smoker etc. The results will be sent to their GP in confidence.
And, now a trading halt ?
https://www.nzx.com/files/attachments/212611.pdf
“The Chief Execitive Officer for Pacific Edge Diagnostics USA, Jackie Walker, says:“Not only does this publication provide further evidence of the superior sensitivity of Cxbladder Detect in diagnosing bladder cancer compared other other non-invasive tests, but most importantly it is the first piece of comparative data that includes UroVysion FISH, a molecular test that is widely used by clinicians and physicians in the US. As we expected, Cxbladder Detect proved to be better at detecting bladder cancer than all the non-invasive tests currently being used in the US and provides an effective adjunt to cystoscopy, and this is what clinicians have been looking for”